IL152554A0 - PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII - Google Patents

PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII

Info

Publication number
IL152554A0
IL152554A0 IL15255401A IL15255401A IL152554A0 IL 152554 A0 IL152554 A0 IL 152554A0 IL 15255401 A IL15255401 A IL 15255401A IL 15255401 A IL15255401 A IL 15255401A IL 152554 A0 IL152554 A0 IL 152554A0
Authority
IL
Israel
Prior art keywords
factor
pharmaceutical composition
xiii
viia
factor viia
Prior art date
Application number
IL15255401A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL152554A0 publication Critical patent/IL152554A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IL15255401A 2000-05-10 2001-05-10 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII IL152554A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000778 2000-05-10
DKPA200000771 2000-05-10
DKPA200000871 2000-06-06
PCT/DK2001/000322 WO2001085198A1 (en) 2000-05-10 2001-05-10 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII

Publications (1)

Publication Number Publication Date
IL152554A0 true IL152554A0 (en) 2003-05-29

Family

ID=27222387

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15255401A IL152554A0 (en) 2000-05-10 2001-05-10 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII

Country Status (17)

Country Link
US (3) US20030092627A1 (de)
EP (3) EP1282438B1 (de)
JP (2) JP2003532684A (de)
CN (1) CN1304049C (de)
AT (2) ATE311198T1 (de)
AU (3) AU2001258228B2 (de)
BR (1) BR0110659A (de)
CA (1) CA2406583A1 (de)
CZ (1) CZ20023667A3 (de)
DE (2) DE60115422T2 (de)
DK (1) DK1282438T3 (de)
ES (2) ES2247106T3 (de)
HU (1) HUP0301868A3 (de)
IL (1) IL152554A0 (de)
NO (1) NO20025355L (de)
PL (1) PL365042A1 (de)
WO (2) WO2001085198A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ529856A (en) * 1999-10-04 2005-09-30 Chiron Corp Stabilized liquid polypeptide-containing pharmaceutical compositions
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
ES2429523T3 (es) 2000-09-13 2013-11-15 Novo Nordisk Health Care Ag Variantes del factor VII de coagulación humana
AU2001287550B2 (en) 2000-09-13 2007-03-22 Novo Nordisk Health Care Ag Human coagulation factor VII variants
EP1337267B1 (de) * 2000-11-03 2007-04-25 ZymoGenetics, Inc. Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
WO2002038162A1 (en) 2000-11-09 2002-05-16 The Scripps Research Institute MODIFIED FACTOR VIIa
AU2002226004A1 (en) * 2000-11-10 2002-05-21 Zymogenetics Inc. Use of factor xiii for treating hemophilia b
KR20030078901A (ko) * 2001-02-05 2003-10-08 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드 및 인자 ⅷ 폴리펩티드의 조합 사용
EP1379271A1 (de) * 2001-02-21 2004-01-14 ZymoGenetics, Inc. Therapie des von willebrand syndroms
IL160703A0 (en) * 2001-09-10 2004-08-31 Zymogenetics Inc Method for treating coumarin-induced hemorrhage
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003039581A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
ES2325653T3 (es) * 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
KR101006070B1 (ko) * 2001-12-21 2011-01-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 액체 조성물
DK2283856T3 (da) 2002-06-21 2017-11-20 Novo Nordisk Healthcare Ag Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
EP2174663A1 (de) 2003-01-08 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Stabilisierte wässrige Zusammensetzungen mit Gewebefaktor-Inhibitor (TFPI) oder Gewebefaktor-Inhibitorvariante
ATE547114T1 (de) 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
KR101293503B1 (ko) 2003-08-14 2013-08-07 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ｖｉｉ 폴리펩티드의 액상 수성 약학적 조성물
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
EP1750758A1 (de) * 2004-05-11 2007-02-14 Novo Nordisk Health Care AG Verwendung von faktor viia zur behandlung von verbrennungstraumata
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
US20080176789A1 (en) * 2004-08-27 2008-07-24 Novc Nordisk Healthcare A/G Purification of Factor Xlll Polypeptides From Biological Materials
EP1791555B1 (de) * 2004-09-10 2013-03-13 Pharmaorigin ApS Verfahren zur Behandlung von lokalen trachealen, bronchialen oder alveolären Blutungen oder Hämoptyse
ATE540974T1 (de) 2004-11-23 2012-01-15 Zymogenetics Inc Reinigung des rekombinanten menschlichen faktors xiii
US20090130086A1 (en) * 2005-02-28 2009-05-21 Novo Nordisk Health Care Ag FXIII Variants with Improved Properties
US20080161425A1 (en) * 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor
EP2004214B1 (de) 2006-03-16 2012-11-07 STELLARIS PHARMACEUTICALS Aps Lokale behandlung mit faktor vii
EP2046372A2 (de) * 2006-07-17 2009-04-15 Novo Nordisk Health Care AG Faktor-viia-analoga mit erhöhter aktivität zur behandlung von thrombozytopenie
EP2147096B1 (de) * 2007-04-13 2015-03-25 Catalyst Biosciences, Inc. Modifizierte Faktor-VII-Polypeptide und Verwendungen davon
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
PL2268267T3 (pl) 2008-04-21 2017-12-29 Novo Nordisk Health Care Ag Kompozycja sucha transglutaminazy
EP2149603A1 (de) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und ihre Verwendung zur Behandlung von Blutungsstörungen
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
BR122021014783B1 (pt) * 2008-12-19 2023-03-14 Baxalta GmbH Peptídeo que se liga a tfpi, uso do peptídeo, composição farmacêutica e método para purificação de tfpi
BR112012023559A2 (pt) * 2010-03-19 2017-10-17 Baxter Healthcare Sa inibidores tfpi e métodos de uso
KR20130099027A (ko) 2010-08-05 2013-09-05 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 혈전용해 및 응고억제 특성을 갖는 단백질 융합 구조물
KR20140143191A (ko) 2012-03-21 2014-12-15 백스터 인터내셔널 인코포레이티드 Tfpi 저해제 및 사용 방법
EP2881463A1 (de) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Faktor-IX-Varianten mit Gerinnungsaktivität in Abwesenheit ihres Cofaktors und/oder mit erhöhter F.IX-Gerinnungsaktivität und ihre Verwendung zur Behandlung von Blutungsstörungen
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP7444059B2 (ja) 2018-07-25 2024-03-06 ソニーグループ株式会社 血液凝固系解析装置
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
JPH0780783B2 (ja) * 1985-11-26 1995-08-30 ノボ ノルディスク アクティーゼルスカブ 出血障害の治療のための第▲ＶＩＩ▼ａ因子を含有する治療組成物
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
HUT67693A (en) * 1991-10-11 1995-04-28 Novo Nordisk As Hemostatic composition for arresting local bleedings
ATE171071T1 (de) * 1991-12-31 1998-10-15 Zymogenetics Inc Verfahren und zusammensetzungen zur verminderung von blutverlust
EP0651655A4 (de) * 1992-07-24 1996-05-29 Oklahoma Med Res Found Blockierung der protein c aktivierung reduziert den blutverlust in mikrogefässen bei chirurgischen eingriffen.
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
EP0885020A1 (de) * 1996-02-20 1998-12-23 Cohesion Corporation Verbindungen zum gewebeverschluss und methoden zu deren gebrauch
WO1998058661A1 (en) * 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
EP1041999A1 (de) * 1997-12-23 2000-10-11 Nuvas LLC Thrombogene polypeptid-chimären und konjugate, die eine von der assoziation mit vaskulärem endothelium abhängige aktivität besitzen
JP2002514433A (ja) * 1998-05-14 2002-05-21 バッテル メモリアル インスティテュート トランスジェニック植物由来ヒト凝血因子
EP1148427A1 (de) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Methode und System zur Erzeugung eines Lesezeichen-Knopfs in einem Web-Browser mit der Darstellung eines vom Benutzer ausgewählten Teils der zugehörigen Datei
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
KR20030078901A (ko) * 2001-02-05 2003-10-08 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드 및 인자 ⅷ 폴리펩티드의 조합 사용
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
EP1446150A1 (de) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmazeutische zusammensetzung mit faktor-vii- polypeptiden und protein-c-inhibitoren
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物

Also Published As

Publication number Publication date
EP1593389A1 (de) 2005-11-09
EP1282438B1 (de) 2005-08-03
EP1282438A1 (de) 2003-02-12
ATE311198T1 (de) 2005-12-15
DE60112429D1 (de) 2005-09-08
WO2001085198A1 (en) 2001-11-15
JP2003532684A (ja) 2003-11-05
US20070280920A1 (en) 2007-12-06
BR0110659A (pt) 2003-02-11
ES2254414T3 (es) 2006-06-16
CN1429117A (zh) 2003-07-09
EP1282439B1 (de) 2005-11-30
DE60112429T2 (de) 2006-06-01
US20030092627A1 (en) 2003-05-15
HUP0301868A3 (en) 2006-11-28
NO20025355D0 (no) 2002-11-08
PL365042A1 (en) 2004-12-27
HUP0301868A2 (hu) 2003-08-28
DK1282438T3 (da) 2005-11-14
AU2001258230A1 (en) 2001-11-20
AU2001258228B2 (en) 2006-01-12
CA2406583A1 (en) 2001-11-15
AU5822801A (en) 2001-11-20
CN1304049C (zh) 2007-03-14
JP2004505016A (ja) 2004-02-19
DE60115422T2 (de) 2006-08-17
US20060199766A1 (en) 2006-09-07
ES2247106T3 (es) 2006-03-01
DE60115422D1 (de) 2006-01-05
ATE300953T1 (de) 2005-08-15
NO20025355L (no) 2003-01-09
WO2001085199A1 (en) 2001-11-15
CZ20023667A3 (cs) 2003-04-16
EP1282439A1 (de) 2003-02-12

Similar Documents

Publication Publication Date Title
IL152554A0 (en) PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII
HK1059215A1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
AU6751101A (en) Topical agent for dermatological use
GB9907461D0 (en) Neurite regeneration
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
HK1067298A1 (zh) 應用於治療皮膚和/或粘膜損傷的體表應用的藥物組合物；組合物在治療皮膚和/或粘膜損傷中的用途和化合物在治療皮膚和/或粘膜損傷中的用途
EP1037918A4 (de) Verfahren und zusammensetzungen zur steigerung der effizienz von impfstoffen unter verwendung von chemokinen
HUP0303936A3 (en) Novel composition and use
WO2001022917A8 (en) Effervescent compositions comprising nimesulide
IT1319685B1 (it) Formulazioni alimentari ad elevato contenuto di calcio.
HUP0002154A3 (en) Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
AUPR626201A0 (en) A composition for use in prophylaxis and/or treatment
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
WO2001060344A3 (en) Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections
AU2002237251A1 (en) A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv
SI1313489T1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
AUPR611201A0 (en) A composition for use in prophylaxis and/or treatment
ZA200208695B (en) Pharmaceutical composition comprising factor VIIa and factor XIII.
CA96622S (en) Pouch, primarily containing cleaning composition(s), fabric care composition(s) or the like
GB0004648D0 (en) Compositions and mixtures for the treatment of skin
MX9709941A (es) Nueva composicion farmaceutica con efecto anestesico.
GB0013240D0 (en) Novel composition and use
GB0013238D0 (en) Novel composition and use
GB0013236D0 (en) Novel composition and use